Menarini Stemline at ESMO 2023
At the Menarini Group, we’re committed to making a difference in the lives of patients with difficult-to-treat cancers who have significant unmet medical needs.
We are looking forward to sharing ideas and scientific knowledge about cancer, networking and furthering our understanding about improving patient outcomes through better detection, personalized medical management and the development of precision medicines.
Join us to discuss the unmet medical needs of patients with ER+/HER2- advanced breast cancer.
We look forward to meeting with you in Madrid! Visit us at Booth 745:
Unmet medical need in breast cancer
Breast cancer is the most frequent malignancy among women and is a heterogeneous disease characterized by various histopathological and molecular features, that result in different diagnosis, clinical outcomes and response to interventions. The global incidence has been rising in the last decades and this trend is likely to continue.
HR+/HER2- is the most common subtype of breast cancer and, according to a recent statistic, accounts for 68% of cases between women (NIH data). Endocrine therapy (ET) is the mainstay of treatment for HR positive breast cancer and has the objective of reducing hormone levels to inhibit ERs and/or PRs tumor signaling. Some patients do however develop ET-resistance after this treatment. This resistance involves the development of mutations in the ESR1 gene, and is associated with more severe prognosis. This mutation, and the subsequent acquired resistance to therapy, represents a high unmet medical need which requires novel management approaches to address this and improve outcomes for patients.